TG Therapeutics is a biopharmaceutical company that develops and markets treatments targeting B-cell diseases. The company's commercial product is BRIUMVI, a monoclonal antibody used to treat relapsing forms of multiple sclerosis in adults, and maintains a pipeline of investigational therapies including an intravenous anti-CD20 antibody, an oral BTK inhibitor, and a bispecific antibody candidate. The company operates through licensing agreements with several pharmaceutical partners and is based in North Carolina.

entry readiness 1 · NOT READY · exit proximity 23

Value area 49.73–58.56 · 2% of 120d volume overhead · clean runway